Treatment Duration for Pulmonary Embolism with Active Cancer
Initial Treatment Phase
- The American Society of Hematology recommends that patients with pulmonary embolism and active cancer receive extended anticoagulation for as long as the cancer remains active, rather than stopping at 3-6 months, with a conditional recommendation and low certainty evidence 1, 2
- For the initial 3-6 months, DOACs (apixaban, edoxaban, or rivaroxaban) are suggested over LMWH for short-term treatment in most cancer patients, according to the American Society of Hematology 1, 2
- LMWH remains preferred over vitamin K antagonists (VKA) for patients who cannot use DOACs, as recommended by the American College of Chest Physicians (Grade 2B) and the American Society of Hematology 1, 3, 4
Extended Anticoagulation
- The American Society of Hematology recommends long-term anticoagulation (>6 months) over short-term treatment alone (3-6 months) in patients with active cancer and VTE, with a conditional recommendation and low certainty evidence 1, 2
- For patients requiring long-term anticoagulation, either DOACs or LMWH are suggested, with a conditional recommendation and very low certainty evidence 1, 2
Bleeding Risk Stratification
- For patients with low or moderate bleeding risk, extended anticoagulation is strongly recommended over 3 months (Grade 1B), according to the American College of Chest Physicians 6, 7, 3
- For patients with high bleeding risk, extended anticoagulation is still suggested, though the recommendation is slightly weaker (Grade 2B), according to the American College of Chest Physicians 6, 7, 3
Practical Implementation
- The American Society of Hematology recommends initiating anticoagulation immediately with DOAC (apixaban, rivaroxaban, or edoxaban) or LMWH, and avoiding DOACs in severe renal impairment (CrCl <30 mL/min) 1, 2
- At 6 months, reassess cancer status, and if cancer remains active, continue anticoagulation indefinitely, as recommended by the American Society of Hematology 1, 2